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Summary Transforming growth factor 11 (TGF-p1l) is a potent modulator of cell proliferation in vitro, and recent studies have demonstrated
its overexpression in several different tumours; nevertheless, the molecular mechanisms of TGF-11 action on cell growth and differentiation
have not been fully elucidated. To clarify the role of TGF-1 and its receptor in human endometrial proliferation and differentiation, TGF-01
expression at both the mRNA and protein levels has been evaluated by using Northern blotting and immunohistochemistry, in both normal
(atrophic, proliferative and secretory) and neoplastic (adenocarcinoma) endometrial samples. This study demonstrates that TGF-1l mRNA
expression is dramatically reduced in endometrial carcinomas with respect to non-neoplastic tissues, whereas the immunohistochemical
expression of TGF-11 is enhanced in the epithelial component of endometrial carcinomas compared with non-neoplastic tissues. These data
suggest that TGF-f1 acts as a paracrine regulator of endometrial cell proliferation and that it may contribute to the carcinogenic mechanisms
of endometrial carcinoma.
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Epithelial and stromal endometrial cells undergo sequential prolif-
eration, differentiation and shedding throughout the menstrual
cycle, and it is well known thatthese changes are driven by coinci-
dent variations of oestrogen and progesterone seric levels. It has
been recently demonstrated that endometrial cells synthesize
cytokines and growth factors that may be derived from constituent
epithelial, mesenchymal or inflammatory cells and which modu-
late endometrial proliferation and differentiation (Smith, 1994).
Such an interactive system, which involves different cell types,
steroid hormones, cytokines and growth factors, should probably
rely on a complex network of intercellular and intracellular
signalling in which cytokines and growth factors play a paracrine,
autocrine or endocrine role. In this regard, several cytokines and
growth factors, such as transforming growth factor a and 1,
insulin-like growth factors, epidermal growth factor, tumour
necrosis factor a, colony stimulating factor 1 and interleukins 1
and 6, have been shown to play a role in the regulation of endo-
metrial growth and differentiation and to interact with steroid
hormones (Tabibzadeh, 1991; Giudice, 1994). Although unbal-
anced oestrogen stimulation of the endometrium, without the
differentiative effects of progesterone, is one of the main aetio-
logic factors of endometrial hyperplasia and carcinoma (Gurpide,
1991), the molecular basis of proliferating diseases is mostly
unknown.
Recent evidence strongly suggest that most human cancers
result from sequential gene damage and subsequent alterations of
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cell growth and differentiation. Moreover, the progression from a
single normal cell to a fully malignant phenotype should require
both the activation of oncogenes and the inactivation of tumour-
suppressor genes (Cline, 1996). In this regard, aberrant expression
or function ofregulatory genes, particularly ofthose encoding for
growth factors and their receptors, surely occurs in several
cancers, including endometrial cancer (Berchuck and Boyd,
1995). Furthermore, loss of growth control is also important
in neoplastic progression and transforming growth factor 01
(TGF-P1) could possibly play a role in carcinogenesis (Roberts
and Sporn, 1990).
TGF-1 belongs to a family ofhomodimeric proteins encoded by
distinct but closely related genes (Massague, 1990). It exerts
different biological effects depending on the target cells (Barnard
et al, 1990); TGF-1 may act as a positive stimulator of growth on
mesenchymal cells and as aninhibitorofepithelial cellproliferation.
Several different tissues and cell lines are able to produce
different TGF-B isoforms and tumours often produce higher
amounts of TGF-1 than their normal counterparts (Coffey et al,
1987; Derynck et al, 1987; Truong et al, 1993; Friess et al, 1994;
Paulin et al, 1995; Christeli et al, 1996; Perlino et al, 1996).
Moreover, several transformed epithelial cells such as hepatocytes
(McMahon et al, 1986), keratinocytes (Reiss and Sartorelli, 1987)
and cells from leukaemia (Niitsu et al, 1988), retinoblastoma
(Kimchi et al, 1988) and bronchial carcinoma (Jetten et al, 1986)
no longer respond to TGF-1 inhibitory effects on cell growth.
In the human endometrium, TGF-,B1 mRNA seems to be
equally distributed in the glands and in the stroma (Murphy et al,
1991) and it seems to modulate the transition from the prolifera-
tive to the secretory phase of the menstrual cycle (Tang et al,
1994). Nevertheless, the role ofTGF-11 in proliferative endome-
trial conditions is still unclear. To give some insight into the role of
this growth factor in endometrial carcinogenesis, we evaluated the
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expression of TGF-P1 at both the mRNA and protein levels by
means of Northern blotting and immunohistochemistry, in both
normal and neoplastic conditions. Furthermore, an immunohisto-
chemical study of TGF-[8l receptor was also performed on the
same tissue samples to correlate the expression of the growth
factor with the cellular localization ofits receptor.
MATERIALS AND METHODS
Patients
This study was performed on 30 tissue samples obtained from 28
women who were admitted to the Department of Obstetrics and
Gynaecology 'R' of the University of Bari School of Medicine in
the years 1995-96. All patients included in this study had not
received hormonal therapy before surgery and should not have
manifested concomitant ovarian lesions. Informed consent was
obtained from all patients.
The patients were divided into three groups. Group 1 included
ten normally menstruating women (mean age 46.5±3.6; range
42-53 years) with subserosal leiomyomas; one ofthem also had an
endometrial polyp (0.8 cm in maximum diameter). These women
underwent hysteroscopy with microbiopsy to exclude the presence
ofrelevant endometrial lesions, and subsequently simple hysterec-
tomy. Among these samples, six were early/mid-proliferative
endometria and four early/mid-secretory endometria. The endome-
trial polyp showed hyperplastic changes and mild cystic dilation of
the glandular component.
Group 2 included five post-menopausal women (mean age: 60.6
± 2.9; range: 55-63 years; median post-menopausal age: 8.8 ± 3.3
years) who underwent hysterectomy with bilateral salpingo-
oophorectomy for uterine prolapse; in these women previous
hysteroscopy with microbiopsy had excluded relevant endometrial
lesions with the exception ofan endometrial polyp (0.6 cm) in one
ofthem. All the samples ofthis group showed histological features
ofendometrial atrophy with the presence of a 'matronal' polyp in
one ofthem.
Group 3 included 13 women (mean age: 62 ± 11; range: 39-81
years) with histologically proven endometrial adenocarcinoma
who underwent hysterectomy, bilateral salpingo-oophorectomy
and selective pelvic lymphadenectomy. This group included seven
well-differentiated (FIGO-GI), five moderately differentiated
(G2) and one poorly differentiated (G3) tumours. With regard to
the histotype, there were seven endometrioid carcinomas, five
of which showed secretory features, three mucus-producing
(colonic type) carcinomas, two adenosquamous carcinomas and
one serous carcinoma.
Soon after surgical removal ofthe uterus, an endometrial sample
was taken from all specimens including the two polyps, snap-
frozen and cryopreserved in liquid nitrogen for RNA extraction.
The remaining tissue samples were fixed in 10% neutral-
buffered formalin for 12-24 h, embedded in paraffin and stained
with haematoxylin-eosin. The histological preparations were
reviewed to compare the histological dating with the clinical
dating in menstruated women, to specify the histological subtype
of endometrial carcinomas and define tumour grade. A single
paraffin block per case was then selected for immunostaining
based on good morphological preservation.
A sample ofhistologically proven normal human liver, obtained
during cholecystectomy, was also included in this study and
submitted to mRNA extraction.
RNA extraction and Northern analysis
Frozen tissue samples were pulverized and cellular RNA was
extracted using the guanidinium isothiocyanate-caesium chloride
procedure (Chirgwin et al, 1979).
Total RNA (25 jig) isolated from the tissues was separated
on agarose/formaldehyde gel, transferred to a nitrocellulose-
supported membrane and subsequently hybridized as described
previously (Perlino et al, 1996). Autoradiographs were quantitated
by laser densitometry using 28S rRNA gene as standard (Bhatia et
al, 1994). For this purpose the blots were stripped in 0.1% boiling
sodium dodecyl sulphate (SDS) and reprobed with the radio-
labelled 28S cDNA probe. The ratio of the 2.5-kb-long TGF-,31
mRNA band intensity over the 28S band intensity was calculated
in each sample to account for RNA loading variations. RNA
expression was evaluated as the percentile ratio between each
patient and the proliferative endometrial tissue isolated from the
normal controls present in the same filter. Finally the mean value
of three or four experiments for each patient was calculated by
statistical analysis.
The variability was always less than 10% in different
measurements.
HL60 cells
Human promyelocytic leukaemia (HL60) cells were grown in
RPMI-1640 medium (Gibco, Life Technologies, Italy), with
50,g ml-' gentamicin, 2 mm glutamine and 15% inactivated fetal
calf serum, at 37°C in presence of 5% carbon dioxide. Total
RNA from differentiated cells (Feuerstein and Cooper, 1984) was
prepared, as previously described, 24 h after incubation with
160 nm TPA (phorbol-12-myristate-13-acetate, Sigma, Italy).
Immunohistochemistry
Sections (5 jim) were cut from the selected paraffin blocks,
collected on poly-L-lysine-coated slides and immunostained for
TGF-f1 and TGF-,1 receptor type II (TGF-Plr) using an alkaline
phosphatase-anti-alkaline phosphatase (APAAP) technique (Van
Noorden, 1986) afterpretreatment ofthe tissue sections with 2.5%
Ficin (Sigma, Milan, Italy) for 8 min at room temperature. A
mouse monoclonal antibody anti-TGF-4l (clone: TB21, dilution
1:1000) and a rabbit antiserum against TGF-,Blr (dilution 1:100),
both available from Diagnostic Brokers Associated (Milan, Italy),
were used as primary antibodies.
Control sections for specificity included staining of positive
controls (previously stained sections ofmyometrium) and ofnega-
tive control sections, which were incubated with the immuno-
globulin fraction of normal mouse and rabbit sera in place of the
specific immunoreagent.
Evaluation ofTGF-p1 andTGF-P1 r immunoreactivity
In all casesTGF-P1 andTGF-Pjlr immunoreactivity was indepen-
dently evaluated in the stromal and in the epithelial component
by three pathologists (EM, AN, MGF); TGF-01 and TGF-flr
immunoreactivity was assessed in ten randomly selected areas
of the same histological section in each case, observed at 40x
magnification.
The extent of the immunoreactivity within each cell compo-
nent, meant as the mean percentile value ofimmunoreactive cells
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Figure 1 Northern blot analysis of TGF-fl RNA. Total RNA (25 igg per lane)
from human liver, TPA-differentiated HL-60 cells and from human
endometrial tissue samples was size fractionated, blotted and hybridized.
Hybridization was carried out with 3 x 106 c.p.m. ml-1 of a-32P-CTP-labelled
TGF-,lB cDNA probe. To normalize the RNA amount in each sample, filters
were stripped and hybridized again with labelled 28S cDNA probe. On the
right TGF-, and 28S size are shown on the basis of 18S and 28S migration.
Lane 1, human liver; lane 2, TPA differentiated HL-60 cells; lanes 3-5,
endometrial adenocarcinomas; lane 6, endometrial tissue from a post-
menopausal patient; lane 7, endometrial tissue from a patient in the
proliferative phase; lane 8, endometrial tissue from a patient in the secretory
phase; lane 9, endometrial polyp
independently obtained by the observers, was semiquantitatively
scored as follows: 0, absence of immunoreactive stromal/
epithelial cells; 1, 1-10% immunoreactive stromal/epithelial cells;
2, 11-50% immunoreactive stromal/epithelial cells; 3, >50%
immunoreactive stromal/epithelial cells.
To calculate the mean semiquantitative value and s.e.m. within
each group, the same quantitative values independently obtained
by the three observers were added together and the mean values
and s.e.m. of each group was obtained and reported in the 0-3
arbitrary scale.
Statistical analysis
Expression data are reported as the means ± s.e.m. for the indi-
cated experiments. Statistical significance among the categories
was determined by non-parametric procedure using the
Kruskal-Wallis H test. All experiments were repeated at least three
times.
RESULTS
RNA expression analysis
Steady-state levels of TGF-j31 mRNA were quantitated by
Northern blotting ofRNA from endometrial neoplastic and normal
tissues. Because ofthe very low amount ofRNA obtained from the
tissue samples, it was necessary to analyse total RNA rather than
poly(A+)RNA.
Figure 1 shows the results of a typical Northern analysis of
TGF-PI mRNA. A 2.5-kb-long transcript was found in all
samples. Total RNA extracted from TPA differentiated HL60 cells
(lane 2) and human liver RNA (lane 1) were used as positive and
negative controls of TGF-,1 gene expression, respectively, as
TGF-,B1 is secreted from TPA-differentiated HL60 cells but not
from normal human liver (Derynck et al, 1985). As expected,
TGF-jI mRNA expression in endometrial tissues was very low
(14%) compared with the expression in TPA-differentiated HL60
cells. Moreover, a fivefold increase ofTGF-,1 mRNA expression
was demonstrated in endometrial samples compared with the
normal human liver.
The autoradiographic analysis of Northern hybridization
showed a statistically significant (P < 0.005) variation of the
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Figure 2 TGF-pl expression in endometrial adenocarcinoma. The ratio of
TGF-L2 absorbance with the corresponding 28S signal was calculated and
the mean percentile values calculated with respect to the normal follicular
tissue are reported. NP, mean percentile value of TGF-P1 expression in
endometrial normal tissue isolated from six patients in the proliferative phase;
ECl-EC13, mean percentile values of TGF-pl expression in the tissue from
13 patients affected by endometrial adenocarcinoma
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Figure 3 TGF-41 mRNA expression in endometrial tissues. The ratio of
absorbance of TGF-1l with the corresponding 28S signal was calculated and
the mean percentile values with respect to the normal follicular tissue, are
reported. NP, mean percentile value of TGF-, expression in normal tissue
isolated from six patients in the proliferative phase; SP, mean percentile
values of TGF-,B expression in the endometrial tissue from four patients in the
secretory phase; AT, mean percentile values ofTGF-P expression in the
endometrial tissue from five post-menopausal patients; EC, mean percentile
values of TGF-1 expression in the endometrial tissue from 13 patients
affected by endometrial carcinoma; EP, mean percentile values of TGF-l
expression in the tissue isolated from two patients affected by benign
endometrial polyps.
expression of TGF-,1 mRNA in the different neoplastic (lanes
3-5) and non-neoplastic tissues (lanes 6, 8 and 9) in comparison
with the RNA from samples ofproliferative endometrium (lane 7)
used as normal control. To normalize the differences due to mRNA
loading and transfer, the same blots were dehybridized and rehy-
bridized again with a human 28S rRNA cDNA probe. The values
ofTGF-PI expression in all tissues were related to the 28S RNA
expression accounting for the RNA loading in each sample and
calculated as a percentage of control (normal proliferative tissue).
Finally, the mean values of at least three separate measurements
for each patient are reported in Figures 2 and 3.
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Table 1 TGF-,B1 immunoreactivity in the endometrium
Tissue Glands Stroma
P < 0.005 P < 0.25
NP (n = 6) 0.50 (0.20) 0.83 (0.15)
SP (n= 4) 0.75 (0.41) 1.00 (0.35)
AT (n =5) 0.40 (0.30) 1.20 (0.20)
EC (n = 13) 1.61 (0.28) 1.08 (0.20)
EP (n =2) 1.00 (1.00) 2.0 (0.71)
The mean values of TGF-fi1 percentile immunoreactive cells are reported in
the glands and stromal compartment of the endometrial tissue. s.e.m. is
reported in brackets. NP, proliferative endometria; SP, secretory endometria;
AT, post-menopausal endometria; EC, endometrial carcinomas; EP,
endometrial polyps.
Figure 4 TGF-j1 immunoreactivity in endometrial tissues. The mean
values ofTGF-p1 percentile immunoreactive cells are separately reported for
the epithelial and stromal cells of the endometrial tissues from six patients in
the proliferative phase (NP), four in the secretory phase of the menstrual
cycle (SP), five post-menopausal patients (AT), 13 patients affected by
endometrial carcinoma (EC) and two with endometrial polyps (EP).
C, epithelium; 1, stroma
As shown in Figure 2, a dramatic decrease of TGF-,B1 steady-
state level mRNA expression was detected in all cases of endo-
metrial carcinoma compared with the samples of proliferative
endometrium. The percentile reduction of TGF-P1 expression
ranged from 9% up to 88%, with an average value of 42%. No
direct correlations were found between the decrease in TGF-11
expression and tumour differentiation; interestingly, the most
reduced level of TGF-pl mRNA expression was found in the
poorly differentiated carcinoma ofthe serous type.
We also tested TGF-f1 expression in normal tissues from four
patients in the secretive phase and from the five post-menopausal
patients (Figure 3). We could detect a drastically decreased (32%)
expression of TGF-P in secretory endometria compared with
normal proliferative tissues. On the contrary, highly increased
(300%) expression in the atrophic tissues was found.
Moreover, we also tested TGF-5l mRNA expression in the two
endometrial polyps obtained from a woman with proliferative
endometrium and from a post-menopausal woman. A statistically
significant (P < 0.05) increase (195%) ofTGF-,1 mRNA expres-
sion was demonstrated in both samples.
TGF-,1 - immunohistochemistry
The results of the semiquantitative evaluation of TGF-f31
immunoreactivity are schematically illustrated in Figure 4, and the
corresponding mean values are reported in Table 1. No statistically
significant correlations were found between the extent ofTGF-P1
positivity in either the epithelial and stromal compartments
(Figure 5) and the degree of tumour differentiation or the tumour
histotype. Epithelial cells of endometrial carcinoma demonstrated
the highest percentages of TGF-,B1 immunoreactive cells in the
whole series of cases, followed by the epithelial cells from
endometria in the secretory, proliferative and post-menopausal
phases. A trend for higher TGF-,B1 positivity in both the stromal
Figure 5 TGF-,1 immunoreactivity in stromal and neoplastic epithelial cells
from endometrial adenocarcinoma. Alkaline phosphatase-anti-alkaline
phosphatase (APAAP) anti-TGF-f1; 250x
and epithelial tumour cells was detected in the typical
endometrioid histotype compared with mucus-producing,
adenosquamous and serous carcinoma.
In tissue samples from women in their early/mid-proliferative
phase, the percentage of TGF-PI-positive stromal cells (mean
value = 0.83) was similar to that in the glandular epithelial cells
(mean value = 0.5) (Figure 6).
Samples from women in the secretory phase demonstrated
approximately the same percentage of TGF-Pl-positive cells in
stromal (mean value = 1) and epithelial endometrial cells (mean
value = 0.75).
TGF-f1 immunoreactivity in tissue samples from post-
menopausal women was detected in stromal endometrial cells
more than in glandular epithelial cells: the mean value for TGF-
fi1-immunoreactivity in the stromal compartment of post-
menopausal women was 1.25, whereas the mean value for the
epithelial component was 0.5.
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Figure 6 TGF-j1 immunoreactivity in normal endometrial glandular and
stromal cells. Alkaline phosphatase-anti-alkaline phosphatase (APAAP)
anti-TGF-1l; 250x
Overall, TGF- 13 immunoreactivity was comparatively higher in
the stromal compartment than in the epithelial cells of post-
menopausal, early/mid-proliferative and secretory endometria;
only endometrial carcinoma epithelial tumour cells displayed
higher percentages of TGF-pl immunoreactivity than stromal
cells. The highest percentages ofTGF- I-immunoreactive stromal
cells were detected in the tissues from the two endometrial polyps,
followed by the samples ofpost-menopausal women, endometrial
carcinoma, secretory and proliferative endometria.
In all cases of the present series the immunopositivity was
exclusively detected in the cell cytoplasm. Scattered inflammatory
cells were present in atrophic and neoplastic endometria and
occasionally demonstrated TGF-i1 immunoreactivity. These rare
TGF- 1-positive inflammatory cells were not included in the
semiquantitative evaluations.
TGF-1 receptor (TGF-p1 r) - immunohistochemistry
The results of the semiquantitative evaluation of TGF-,1lr
immunoreactivity are schematically illustrated in Figure 7, and the
corresponding mean values are reported in Table 2. As for TGF-
P1, TGF-flr immunoreactivity was exclusively detected in the cell
cytoplasm.
The mean values for the percentages of TGF-4lr-positive cells
were 0.77 and 1.61, respectively, in the stromal and in the epithe-
lial compartment ofendometrial carcinoma (Figure 8).
In early/mid-proliferative endometrial samples, TGF-Plr posi-
tivity mean value was 0.33 forthe stromal component and 0 for the
epithelial component.
No TGF-,lr positivity was found in the stromal compartment of
secretory endometria (mean values = 0 in the stromal component
and 0.25 in the epithelial component).
Overall, TGF-,Blr immunoreactivity was predominantly detected
in the stromal compartment compared with the epithelial compo-
nent and in the groups of women in post-menopausal stage and in
Figure 7 TGF-l1 r immunoreactivity in endometrial tissues. The mean
values of TGF-f1 r percentile immunoreactive cells are separately reported
for the epithelial and stromal cells of the endometrial tissues from six patients
in the proliferative phase (NP), four in the secretory phase of the menstrual
cycle (SP), five post-menopausal patients (AT), 13 patients affected by
endometrial carcinoma (EC) and two with endometrial polyps (EP).
E, epithelium; 1, stroma
the early/mid-proliferative phase, whereas TGF-,lr-positivity of
epithelial cells overcame the positivity in stromal cells in the
groups of women with secretory endometrium and with endome-
trial carcinoma.
When comparing the mean values ofthe percentages ofTGF-,Blr-
immunoreactive cells with those of TGF-,IB-immunoreactive cells,
the groups ofwomen inpost-menopausal stage andwith endometrial
carcinoma showed very similar mean values both in the epithelial
and in the stromal compartments. In the groups of women in their
early/mid-proliferative or secretoryphases, the mean values ofTGF-
,B1-immunoreactive cells were much higher than those ofTGF-,lr-
immunoreactive cells, both in the epithelial and in the stromal cells.
DISCUSSION
In this paper we have shown decreasedTGF-PI mRNA expression
in endometrial carcinoma compared with proliferative endometria.
On the contrary, immunohistochemical data demonstrate increased
protein expression in both stromal and epithelial cells in endome-
trial carcinoma.
Table 2 TGF-1lr immunoreactivity in the endometrium
Tissue Glands Stroma
P< 0.005 P< 0.005
NP (n = 6) 0.00 (0.00) 0.33 (0.19)
SP (n= 4) 0.25 (0.21) 0.00 (0.00)
AT (n =5) 0.60 (0.20) 1.00 (0.05)
EC (n= 13) 1.61 (0.25) 0.77 (0.12)
EP (n 2) 0.00 (0.00) 1.00 (0.05)
The mean values of TGF-31r percentile immunoreactive cells are reported in
the glands and stromal compartment of the endometrial tissue. s.e.m. is
reported in brackets. NP, proliferative endometria; SP, secretory endometria;
AT, post-menopausal endometria; EC, endometrial carcinomas; EP,
endometrial polyps.
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Figure 8 TGF-,1 r immunoreactivity in epithelial cells from endometrial
adenocarcinoma. Alkaline phosphatase-anti-alkaline phosphatase (APAAP) anti-TGF-f1 r; 250x
Although mRNA expression generally parallels the degree of
translation, in ourstudy the increase ofTGF-1 protein did not seem
to be associated with RNA increase. This seems to suggest that
alterations ofTGF-f expression in carcinomas is a post-transcrip-
tionally regulated event. As immunolocalization reveals sites of
mature protein rather than the site ofits synthesis, one may specu-
late thatTGF-0 is activated in theglands ofendometrial carcinoma.
These results clearly indicate a down-regulated expression of
TGF-fI, at least at the mRNA level in endometrial carcinoma.
The most widely studied role of TGF-f is its regulatory effect
on cellproliferation in both normal and transformed tissues: recent
studies have shown that although TGF-131 is a potent inhibitor of
epithelial cell proliferation in vitro, it is expressed athigher levels
in several tumourtypes (McMahon etal, 1986;Truong etal, 1993;
Christeli et al, 1996; Friess et al, 1994; Perlino et al, 1996). 'In
situ' hybridization and immunohistochemical studies demon-
strated that endometrial cells do express TGF-0 mRNA and
protein(Chegini et al, 1994); theexpression ofTGF-,BmRNA was
documented both in normal endometrial tissue (Marshburn et al,
1994) and in human carcinoma cell lines (Boyd and Kaufman,
1990). Nevertheless, the role ofTGF-1 in theaetiopathogenesis of
endometrial proliferative conditions has not been clarified yet.
Ourfindings ofdown-regulatedTGF-,1 mRNA in endometrial
carcinoma is in agreement with the results of anotherstudy (Boyd
and Kaufman, 1990), which demonstrated 'in vitro' an inverse
correlation betweenTGF-131 mRNAexpression and tumourdiffer-
entiation in different subtypes of an endometrial carcinoma cell
line (HEC). In the study of Boyd and Kaufman (1990), TGF-3
expression seemed to be inversely correlated with tumour differ-
entiation as TGF-,BmRNA was more expressed in the less differ-
entiated subtype of endometrial carcinoma cells than in the most
differentiated ones.
Although we were not able to detect significant 'in vivo' corre-
lation between TGF-,B1 mRNA expression and tumour grade, we
did observe the lowest expression in the most aggressive (serous)
and less differentiated (G3) endometrial carcinoma. This incon-
gruence might be ascribed to the limited number of endometrial
carcinomas included in the present series or to different mRNA
expression in 'in vitro' and 'in vivo' conditions. In this context, it
should be underlined that complex interactions among TGF-,l,
steroid hormones and other cytokines may take place 'in vivo',
thusjustifying for these different results.
On the other hand, Gold et al (1994) have shown a statistically
significant increase in 'in vivo' immunostaining for all three TGF-
f3 isoforms in endometrial glandularepithelium in complexhyper-
plasia and carcinoma. The authors suggested a possible paracrine
role ofTGF-P in hyperplastic and malignant endometrial lesions.
Our study lends further support to this hypothesis, although the
results of these two studies are not in complete agreement. The
discrepancies might be due, at least in part, to the different
methods used in the two studies: Gold et al detected TGF-P1
mRNA expression by means of 'in situ' hybridization instead of
Northern blotting analysis. Furthermore, that study quantitatively
evaluated the intensity ofTGF-,13 immunoreactivity, whereas we
measured the percentage ofTGF-PI-immunoreactive cells.
To verify the specificity ofTGF-j1-altered expression we also
measured mRNA levels in endometrial tissues obtained from
patients with endometrial polyps. Interestingly, in such benign
lesions the numberofTGF-, 13-positive cells was higher than in all
othersamples, andTGF-13I mRNAexpression was up-regulated in
endometrial polyps compared with normal proliferative endome-
tria. One could speculate that the down-regulated TGF-1I expres-
sion is a specific effect ofthe endometrial tumoural condition.
Moreover, we investigated the role of this growth factorduring
the physiological changes of uterine tissues throughout the
menstrual cycle. In agreement with other authors (Casey et al,
1996) we found a significantly increased TGF-f mRNA expres-
sion in post-menopausal women. Our immunohistochemical data
showed a parallel increase of TGF-,B1 and its receptor in the
stromal compartment ofatrophic tissues, thus indicating akey role
ofthis growth factor in the control ofcellularatrophy.
In this study we also found a statistically significant decrease of
TGF-,B1 mRNA expression in the secretory phase, whereas both
TGF-,1 and TGF-flr were strongly expressed especially in the
epithelial component from the same patients. Other authors
(Kauma et al, 1990 and Mashbum et al, 1994) have detected
increased TGF-, expression in the late secretory and early prolif-
erative phases. Our immunohistochemical data seem to confirm
these results, thus indicating that during the late proliferative and
the early/mid-secretory phase, a substantial increase in TGF-j
protein expression may lead to growth arrest and induce the transi-
tion from cellular proliferation to differentiation of various
endometrial cell types.
In conclusion, our study corroborates previous investigations
that demonstrated a pivotal role ofTGF-fi1 in both physiological
and neoplastic conditions of the endometrium. TGF-31 seems to
act as a negative regulator of cell growth in the transition from
the proliferative to the secretory phase ofthe menstrual cycle and
in endometrial atrophy. Moreover TGF-1 seems to participate in
the mechanisms of endometrial carcinogenesis, but its role and
interactions with other regulatory molecules needs to be further
elucidated.
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